In 2021, two targeted therapies have been approved for EGFR exon 20 insertion mutant NSCLC: the small molecule EGFR kinase inhibitor, mobocertinib, and the anti-EGFR-MET bispecific antibody, amivantamab [44,45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.